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Abstract
Objective—To determine medical eligibility for contraceptive use, contraceptive preference, and
acceptance of a copper intrauterine device (IUD) among a cohort of HIV-infected women
receiving antiretroviral therapy (ART).
Methods—All HIV-infected women who received ART and sought contraceptive services at the
Lighthouse clinic, an integrated HIV/ART clinic in Lilongwe, Malawi, between August and
December 2010 were invited to participate in a structured interview. Eligibility and preference for
the following contraceptive methods were assessed: combined hormonal contraceptives,
progestogen-only pills, copper IUD, injectable depot medroxyprogesterone acetate (DMPA), and
contraceptive implants.
Results—The final sample included 281 women; five were pregnant. The remaining 276 women
were eligible for at least three contraceptive methods, with 242 (87.7%) eligible for all five
methods evaluated. After counseling, 163 (58.0%) selected DMPA and 98 (34.9%) selected an
IUD as their preferred contraceptive method. Regardless of their method of choice, 222 (79.0%)
women agreed to have an IUD placed on the same day.
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Conclusion—Most methods of contraception are safe for use by HIV-infected women.
Approximately 80% of the women were willing to receive an IUD. Efforts must be made to
increase education about, and access to, long-acting reversible methods that may be acceptable
and appropriate contraceptive options for HIV-infected women.
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1. Introduction
The prevention of unintended pregnancy among women with HIV infection is critical for
two reasons: to decrease the unnecessary morbidity and mortality associated with an
unintended pregnancy and to reduce the transmission of HIV infection to infants of HIV-
infected mothers. For women with HIV, condoms are often promoted as the contraceptive
method of choice because of the benefits of preventing sexually transmitted infections and
HIV transmission [1]. However, given a pregnancy rate of 18% per year with typical use
among those using condoms alone for contraception [2], a superior strategy is desirable
where a highly effective reversible contraceptive is used in conjunction with condoms to
provide dual protection. Among women in HIV-serodiscordant couples, the use of injectable
contraceptives, such as depot medroxyprogesterone acetate (DMPA), or long-acting
reversible contraceptives (LARC), such as intrauterine devices (IUDs) and implants,
significantly reduces the incidence of pregnancy compared with the use of condoms alone or
oral contraceptives [3]. Given the clear benefits of these methods, it is important to
determine which methods can be safely given to women with HIV and to make a range of
methods available so that women can choose the best method for them.
In 1996, WHO developed the Medical Eligibility Criteria for Contraceptive Use (WHO
MEC), now in its fourth edition [4], to assist providers in determining which contraceptive
methods could be safely used by their clients. Although HIV itself does not restrict the use
of any contraceptive method [4], other common medical conditions, comorbidities, or
medications may limit the options for these women. For example, hormonal contraceptives
are considered to be safe overall for use among women receiving antiretroviral therapy
(ART), but women taking ART regimens that contain ritonavir-boosted protease inhibitors
incur risks with oral contraceptives that may outweigh the benefits because of potential
drug–drug interactions that may impact contraceptive efficacy and drug toxicity.
Among the nonhormonal methods, the copper IUD is considered to be safe for use by
women with HIV and/or AIDS who are stable on ART [4]. A benefit of this non-hormonal
method is that other medications will not impact its contraceptive effectiveness. Studies
[5,6] looking at one particular model of the copper IUD, the copper T380A IUD, found no
increased risk of infection-related or overall complications among HIV-infected women and
no increase in the genital shedding of HIV [7,8]. Unfortunately, despite its high efficacy,
safety, ease of use, cost-effectiveness, and reversibility, fewer than 1% of women in Sub-
Saharan Africa use an IUD [9].
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In Malawi, the prevalence of HIV among women between 15 and 49 years of age is 12.9%
[10], with rates of up to 22.7% among women in urban regions. Concurrently, although
knowledge about contraceptives is almost universal, the prevalence rate for the use of
modern contraceptives is 42% among currently married women using any form of modern
birth control, and an estimated 40.6% of pregnancies are unintended [10], with about one-
third of unintended pregnancies attributed to contraceptive method failure [11]. With the
dramatic increase of women receiving ART in Malawi as a result of Option B Plus [12,13],
a policy that recommends all HIV-positive pregnant women begin and remain on lifelong
ART, medical eligibility for various contraceptive methods in this population has immediate
program and policy implications.
The present study explored the medical eligibility for contraceptive use, preferences for
contraceptives, and acceptance of the IUD among a cohort of HIV-infected women
receiving ART who presented for integrated HIV and family planning services at the
Lighthouse clinic at Kamuzu Central Hospital (KCH) in Lilongwe, Malawi.
2. Materials and methods
The Lighthouse Trust is a center of excellence for integrated HIV management and runs two
clinics, one at KCH and another based at Bwaila Maternity Hospital, in Lilongwe. Both
Lighthouse clinics provide a continuum of HIV-related services from HIV testing to ART
and home-based care. The Lighthouse clinic at KCH has more than 8000 patients who
receive ART and more than 1000 patients who are not yet clinically eligible for ART.
Before initiation of the present study, the capacity for the provision of comprehensive family
planning services was developed because previously only male and female condoms were
available at the clinic for family planning. Education strategies to promote family planning
both among clinical staff and patients were integrated into clinical care at the Lighthouse
clinic. Given that most physicians and clients were well educated about the use of DMPA
and oral contraceptives, new educational strategies focused on the efficacy and safety of
LARC methods, specifically the IUD and contraceptive implants.
The present analysis is based on a subset of data from a randomized clinical trial conducted
at the Lighthouse KCH clinic to compare the copper T380A IUD with DMPA [14]. The
study population consisted of HIV-infected women who attended the Lighthouse clinic at
KCH and desired family planning. All women provided written informed consent prior to
participation in any study activity. For the present analysis, we used cross-sectional baseline
data collected from August 2, 2010, to January 2, 2011, from all women recruited to reach a
sample size of 200.
The clinical trial and its methods have been described previously [14]. Briefly, Lighthouse
staff identified women of reproductive age as they presented for routine ART visits. Women
interested in family planning were screened for participation in the trial as part of the routine
family planning service provision. Women who consented to participate were asked to
complete a structured questionnaire to assess medical eligibility for the use of five modern
contraceptives—combined hormonal contraceptives, progestogen-only pills, copper IUD,
DMPA, and contraceptive implants—through questions based upon the WHO MEC [4].
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Additional questions were included to assess each woman’s first choice of contraceptive, her
willingness to have an IUD placed at the same clinic visit or in the future, and reasons for
declining IUD placement if applicable. The questions were piloted in the local language,
Chichewa, prior to study initiation to ensure question clarity. The questionnaires were
completed on paper in Chichewa and translated into English by the study staff.
All data for the present study were entered in Access 2003 (Microsoft, Redmond, WA,
USA) using a double-entry system and validated using predetermined queries. SPSS version
17.0 (SPSS Inc, Chicago, IL, USA) was used for the statistical analysis. Descriptive
statistics were used to determine the proportion of patients who met the medical eligibility
criteria for the various contraceptive methods, to describe the preference for a specific
contraceptive method, and to evaluate IUD acceptance. A woman was considered to be
eligible for a contraceptive method if the she had a condition classified as Category 1 or 2
[4], indicating that the benefits outweigh the risks. By contrast, a women was considered to
be ineligible if she had a condition classified as Category 3 or 4 [4], indicating that the risks
outweigh the benefits.
Support and formal permission to conduct the study in Malawi was provided by all involved
institutions including the Ministry of Health and the National Health Services Research
Committee in Malawi, the Institutional Review Board at Emory University in Atlanta, USA,
and the Institutional Review Board at the University of North Carolina in Chapel Hill, USA.
3. Results
A total of 281 women were screened for the clinical trial and included in the present
analysis. The mean age was 32.0 ± 5.6 years (range, 18–48 years), the gravidity was 3.7 ±
1.8 (range, 0–11), and the parity was 3.3 ± 1.8 (range, 0–11). Thirteen (4.6%) women had
never used ART, whereas 156 (55.5%) reported ART use for at least 2 years.
Among the 281 women, medical eligibility for the five contraceptive methods evaluated was
high. The proportion of women eligible for contraceptive initiation was 87.2% (n = 245),
95.7% (n = 269), 97.2% (n = 273), 97.9% (n = 275), and 98.2% (n = 276) for combined
hormonal contraceptives, progestogen-only contraceptive pills, IUD, DMPA, and
contraceptive implants, respectively. Five of the 281 women were found to be pregnant at
the time of screening. All 276 non-pregnant women were eligible for at least three methods,
with 242 (87.7%) eligible for all five methods evaluated. Reasons for ineligibility for the use
of a combined hormonal contraceptive included breast-feeding a child under 6 months of
age (n = 20) and use of a ritonavir-containing regimen (n = 6) (Table 1). Of the three women
who were ineligible for IUD use, one woman had active cervicitis and two women had
cervical lesions on examination.
Of 281 women asked about their contraceptive method of choice, 163 (58.0%) women
selected DMPA, 98 (34.9%) chose the IUD, and 16 (5.7%) chose an oral contraceptive.
Irrespective of their first-choice method, 222 (79.0%) of the 281 women were willing to
have an IUD placed on the same day at that visit. Among the 179 women who had stated
either DMPA or oral contraceptives as their preferred option, 122 (68.2%) were willing to
have an IUD placed at that visit. Of the 59 women who declined IUD placement at that visit,
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22 (37.3%) stated that they would be willing to have an IUD placed in the future. Desiring a
different or specific contraceptive method was a common reason for declining IUD
placement (Table 2). Many women also feared IUD placement (n = 15, 25.4%) or had heard
negative things about the IUD (n = 15, 25.4%).
4. Discussion
In the present study, medical eligibility for contraceptives, including LARC methods, among
HIV-positive women attending an ART clinic in Malawi and requesting family planning
provision was assessed using a questionnaire developed to identify potential
contraindications as outlined in the WHO MEC [4]. Medical eligibility in the present cohort
was high for all five family planning methods available, similar to the results found in a
cohort of HIV-positive women in Saint Petersburg, Russia [15]. The study demonstrated that
despite low countrywide IUD use of 0.3% among married women aged 15–49 years [16],
increased uptake of the IUD among HIV-positive women is possible.
The present findings have several important implications for programs and policies aimed at
HIV-positive women in Malawi and in the region. From a program perspective, the
integration of family planning services with HIV care must begin with an education plan for
all clinic staff and clients, with the goal to dispel common misconceptions about
contraceptives and to increase provider comfort with LARC methods. Although the majority
of women selected DMPA as their contraceptive method of choice, almost 35% of the
women indicated a preference for the IUD after appropriate counseling and education about
the various methods. Moreover, even if the IUD was not the first choice, most women were
willing to have an IUD placed. These findings reinforce the results from previous studies [2]
and highlight that when women are given education and a choice, a substantial proportion
may choose the IUD.
From a policy perspective, the demonstration of eligibility for, and acceptability of, multiple
family planning methods has implications for policies on the promotion and use of specific
contraceptives. Concerns have been raised about the potential of hormonal contraceptive
methods, specifically DMPA, to increase HIV acquisition, transmission, and disease
progression [17–21]. Although not every study reached the same conclusion and a recent
WHO consultation [22] found insufficient evidence to support a change in the current
guidelines on the use of hormonal contraceptives among women with HIV or at risk for
HIV, WHO encouraged further investigation of the relationship between hormonal
contraception and HIV risk. Even if this risk is confirmed, the burden from unintended
pregnancy would likely outweigh the potential risk of HIV acquisition [23] in most countries
with high rates of unintended pregnancy and maternal mortality. However, although the use
of hormonal contraceptives is important, effective hormone-free options should also be
promoted, and for some women such methods need to be considered as the first choice. As
demonstrated in the present study, there is willingness to use a nonhormonal IUD among
HIV-positive women. Therefore, proactive policies that promote nonhormonal methods,
such as the IUD, are warranted.
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Another consideration relevant at the policy level is the WHO conclusion [4] that the risks
of hormonal contraceptive pills outweigh their benefits (Category 3) in women who receive
regimens containing ritonavir-boosted protease inhibitors, because potential drug–drug
interactions may alter the pharmacokinetics with potential effects on drug efficacy and
toxicity. The clinical significance of small alterations in hormone bioavailability by non-
nucleoside reverse transcriptase inhibitors (NNRTIs) is unclear [24]. For example, although
the data remain inconclusive, a case report [25] indicated reduced efficacy of an etonogestrel
implant in women using the NNRTI efavirenz. Additional concerns regarding drug–drug
interactions between other ART regimens and hormonal contraceptives could emerge as
ARTs continue to evolve and other regimens are studied. For example, newer antiretroviral
regimens containing the pharmacologic booster cobicistat may affect the cytochrome P450
system and thus influence the plasma concentration and efficacy of hormonal
contraceptives. Given the high eligibility for, and acceptability of, the nonhormonal IUD in
the present population, increasing the availability of this specific method combined with the
provision of education and training will ensure that women with HIV who receive ART will
continue to have access to highly effective contraceptives despite their antiretroviral
regimen.
The present study has several limitations. Only women who expressed an interest in family
planning at the time of the study were included, and hence the study population may not
represent all HIV-infected women with family planning needs. Additionally, individuals
with certain conditions may have been misclassified as eligible because medical eligibility
was determined based on self-reports. The study staff asked sensitive questions about health
and sexual behavior; some participants may have given inaccurate answers and recall bias
may also have influenced the answers. This type of questioning, however, replicates the
history-taking that occurs during a typical clinic visit and therefore likely represents the
situation outside of a study setting. Contraceptive implants were not available during the
study, so no conclusions can be drawn on the preference or eligibility for this method.
Although no clients chose an implant as their first option, it is unclear how the lack of
availability might have influenced their decision.
Despite these limitations, the present study highlights important points for contraception
care among HIV-positive women. First, in line with WHO recommendations [4], we
conclude that most methods of contraception are safe for use by HIV-positive women who
present for family planning services at our ART clinic. Therefore, efforts must be made to
increase the availability of a broad range of contraceptive options. Second, the present
findings highlight the acceptability of the IUD to the majority of HIV-positive women at the
present clinic. The results indicate that there is large, untapped potential to increase IUD use
in this high-risk group, where pregnancy prevention is important and the impact of hormonal
contraception remains unclear. The copper IUD could be promoted as a highly effective
nonhormonal method expanding the contraceptive options for HIV-positive women. Given
that the present family planning services were provided in the context of routine services at a
large, public ART clinic, the findings (in particular in terms of IUD uptake) may be
applicable to other similar settings.
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Table 1
Incidence of conditions in which the use of contraceptive methods is restricted (Category 3 or 4) according to
WHO [4].a
Condition Contraindicated method Frequency in the present study (n = 281)
Breastfeeding (≥ 6 weeks and < 6 months postpartum) CHC 20 (7.1)
Ritonavir use CHC, POP 6 (2.1)
Pregnancy All 5 (1.8)
Hypertension b CHC 2 (0.7)
Migraine without aura, >35 years of age CHC 2 (0.7)
Cervical mass IUD 2 (0.7)
Rifampicin use CHC 1 (0.4)
Stroke CHC, DMPA 1 (0.4)
Active cervicitis IUD 1 (0.4)
Abbreviations: CHC, combined hormonal contraceptive; DMPA, depot medroxyprogesterone acetate; IUD, intrauterine device; POP, progestogen-
only contraceptive pill.
a
Values are given as number (percentage).
b
Systolic blood pressure 140–159 mm Hg, diastolic blood pressure 90–99 mm Hg, or history of hypertension if blood pressure could not be
evaluated.
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Table 2
Reasons for declining IUD placement on the same clinic day (n = 59).a,b
Reason Frequency
Preference for a different method 23 (39.0)
Fear of placement, pain, bleeding, infertility, or infection 15 (25.4)
Heard negative things about the IUD 15 (25.4)
Previously used the IUD and did not like it 4 (6.8)
Uncomfortable having something inside body 3 (5.1)
Need to ask or discuss with partner first 2 (3.4)
Desire to get pregnant 2 (3.4)
Partner does not want to use any contraception 1 (1.7)
A friend was unhappy with the IUD 1 (1.7)
Cannot use IUD because of HIV or another medical condition 0 (0.0)
Does not believe the IUD is effective for birth control 0 (0.0)
Abbreviation: IUD, intrauterine device.
a
Values are given as number (percentage).
b
Participants were able to select more than one reason for declining.
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